Description

Safety profile data from the longitudinal cohort, documenting adverse event rates and severity among oral medicinal cannabis patients over sustained use periods.

Figure 3

Chart

Source Paper

A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two years.

PloS one (2022)

PMID: 36399463

DOI: 10.1371/journal.pone.0272241

Cite This Figure

![Figure 3: Safety profile data from the longitudinal cohort, documenting adverse event rates and severity among oral medicinal cannabis patients over sustained use periods.]()

> Source: Alistair W Vickery et al. "A large Australian longitudinal cohort registry demonstrates sustained safety an." *PloS one*, 2022. PMID: [36399463](https://pubmed.ncbi.nlm.nih.gov/36399463/)

<figure>
  <img src="" alt="Safety profile data from the longitudinal cohort, documenting adverse event rates and severity among oral medicinal cannabis patients over sustained use periods." />
  <figcaption>Figure 3. Safety profile data from the longitudinal cohort, documenting adverse event rates and severity among oral medicinal cannabis patients over sustained use periods.<br>  Source: Alistair W Vickery et al. "A large Australian longitudinal cohort registry demonstrates sustained safety an." <em>PloS one</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36399463/">36399463</a></figcaption>
</figure>

Preuves associées

CBD pour Insomnie

Note A · 103 études